Ken Griffin Harvard Bioscience Inc Call Options Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Call Options

6 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$2.77 - $4.63 $7,756 - $12,964
-2,800 Reduced 70.0%
1,200 $3,000
Q1 2024

May 15, 2024
BUY
$4.02 - $5.39 $16,079 - $21,560
4,000 New
4,000 $16,000
Q3 2023

Nov 14, 2023
SELL
$4.0 - $5.82 $12,800 - $18,624
-3,200 Reduced 24.24%
10,000 $43,000
Q2 2023

Aug 14, 2023
BUY
$4.19 - $6.16 $47,766 - $70,224
11,400 Added 633.33%
13,200 $72,000
Q1 2023

May 15, 2023
BUY
$2.45 - $4.22 $4,165 - $7,174
1,700 Added 1700.0%
1,800 $7,000
Q4 2022

Feb 14, 2023
BUY
$2.12 - $2.86 $212 - $286
100 New
100 $0

Others Institutions Holding HBIO

# of Institutions
102
Shares Held
32M
Call Options Held
1.2K
Put Options Held
1.2K
View Full List

About HARVARD BIOSCIENCE INC

HBIO Quotes by TradingView
  • Ticker HBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 41,636,500
  • Market Cap $116M
  • Description
  • Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as w...
More about HBIO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email